|
|
Volumn 19, Issue 4, 2014, Pages 421-425
|
|
The European medicines agency review of Bosutinib for the treatment of adult patients with chronic myelogenous leukemia: Summary of the scientific assessment of the committee for medicinal products for human use
a
|
|
Author keywords
Bosulif; Bosutinib; Chronic myelogenous leukemia; EMA; European medicines agency
|
|
Indexed keywords
BOSUTINIB;
DASATINIB;
IMATINIB;
NILOTINIB;
ANILINE DERIVATIVE;
BCR ABL PROTEIN;
NITRILE;
PROTEIN KINASE INHIBITOR;
QUINOLINE DERIVATIVE;
ABDOMINAL PAIN;
ANAPHYLAXIS;
ARTICLE;
BLEEDING;
BONE MARROW SUPPRESSION;
CHRONIC MYELOID LEUKEMIA;
COUGHING;
CYTOGENETICS;
DEVICE APPROVAL;
DIARRHEA;
DRUG BIOAVAILABILITY;
DRUG CONTRAINDICATION;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG HALF LIFE;
DRUG INDICATION;
DRUG SAFETY;
EDEMA;
EUROPEAN UNION;
FATIGUE;
FEVER;
FLUID RETENTION;
HEADACHE;
HEART DISEASE;
HUMAN;
LIVER FAILURE;
MALAISE;
NONHUMAN;
PANCREATITIS;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
QT PROLONGATION;
RASH;
RESPIRATORY TRACT INFECTION;
THROMBOCYTOPENIA;
TRIACYLGLYCEROL LIPASE BLOOD LEVEL;
VOMITING;
ANTAGONISTS AND INHIBITORS;
DRUG APPROVAL;
DRUG RESISTANCE;
EUROPE;
FEMALE;
GENETICS;
LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;
MALE;
MIDDLE AGED;
MORTALITY;
MUTATION;
TREATMENT OUTCOME;
ANILINE COMPOUNDS;
DRUG APPROVAL;
DRUG RESISTANCE, NEOPLASM;
EUROPE;
EUROPEAN UNION;
FEMALE;
FUSION PROTEINS, BCR-ABL;
HUMANS;
LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;
MALE;
MIDDLE AGED;
MUTATION;
NITRILES;
PROTEIN KINASE INHIBITORS;
QUINOLINES;
TREATMENT OUTCOME;
|
|
EID: 84898442337
PISSN: 10837159
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.2013-0294 Document Type: Article |
|
Times cited : (10)
|
|
References (9)
|
